Emactuzumab

About SynOx Therapeutics

SynOx Therapeutics is a clinical-stage biotech developing emactuzumab, a best-in-class anti-CSF-1R monoclonal antibody, as a targeted therapy for tenosynovial giant cell tumor (TGCT) and potentially other solid tumors and macrophage-mediated pathologies. The company's strategy is to leverage promising prior clinical data for emactuzumab, originally developed by Roche, to advance a potentially differentiated asset in a niche oncology space with high unmet need. As a private, pre-revenue entity, SynOx's near-term value inflection hinges on the successful clinical development and regulatory approval of its lead candidate. The company operates with a lean, focused model centered on this single asset.

About SynOx Therapeutics

SynOx Therapeutics is a clinical-stage biotech developing emactuzumab, a best-in-class anti-CSF-1R monoclonal antibody, as a targeted therapy for tenosynovial giant cell tumor (TGCT) and potentially other solid tumors and macrophage-mediated pathologies. The company's strategy is to leverage promising prior clinical data for emactuzumab, originally developed by Roche, to advance a potentially differentiated asset in a niche oncology space with high unmet need. As a private, pre-revenue entity, SynOx's near-term value inflection hinges on the successful clinical development and regulatory approval of its lead candidate. The company operates with a lean, focused model centered on this single asset.

Therapeutic Areas

Other Tenosynovial Giant Cell Tumor (TGCT) Drugs